bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-70-2513

Order Name:
Factor V Leiden Mutation

 
Useful For:
This test is intended to provide results for Factor V Leiden (G1691A) mutations as an aid in the diagnosis in individuals with suspected thrombophilia.
 
Methodology:
Multiplex real-time polymerase chain reaction (PCR)
 
AliasesName:
Factor V Leiden (R506Q) Mutation
Activated protein C (APC) resistance mutation 
FVL R506Q mutation 
 
 
 
Test Code:
090-70-2513

Order Name:
Factor V Leiden Mutation

 
Collection Specimen Or Container:
Blood/ K3 EDTA (Lavender Top) 3 mL, 1 tube
 
Specimen Testing Type:
Whole blood, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: N/A
Lipemia: N/A
Icterus: N/A
Other :
  1. Heparin, anticoagulant blood
  2. Whole blood is stored at room temperature longer than 24 hr.
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood, EDTA Room temperature, 22oC to 28oC 24 hours
Refrigerated, 2oC to 8oC 15 days
Frozen, -20oC to -80oC  3 months
 
 
 
Test Code:
090-70-2513

Order Name:
Factor V Leiden Mutation

 
Method detail:
Multiplex real-time polymerase chain reaction (PCR)
 
Schedule:
Test daily
 
Turnaround Time:
Received specimen to reported within 1 day.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
090-70-2513

Order Name:
Factor V Leiden Mutation

 
 
Clinical Information:
The association of Factor V Leiden (G1691A) mutations with an increased risk for venous thrombosis has been well documented. Factor V Leiden (G1691A) refers to the G to A transition at nucleotide position 1691 of the Factor V gene, resulting in the substitution of the amino acid arginine by glutamine in the Factor V protein, causing resistance to cleavage by Activated Protein C (APC). Factor V Leiden (G1691A) mutations are present in 5% of the general population.
 
Reference Value:
No Mutation of the G1691A factor V gene
 
Interpretation:
  1. The results ot the test assay should be interpreted in conjunction with other laboratory and clinical data available to the clinician.
  2. Rare Factor V mutations (A1696G, G1689A, and A1692C) and any additional SNPs in the probe binding region may interfere with the target detection and yield an INVALID result.
 
Clinical Reference:
Manufacturer’s packages insert, Xpert® Factor II & Factor V Assay, August 2017, Cepheid, CA 94089 Sunnyvale, USA.